Amgen has quietly discontinued the development of its Phase I bispecific T-cell engager AMG 794, which the company had been studying for several malignant solid tumors. https://hubs.li/Q02G2k_V0 #pharma #oncology #biospace
BioSpace
Internet News
West Des Moines, Iowa 112,316 followers
The leading source for biopharma news and jobs. Connecting industry pioneers with talented professionals.
About us
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.
- Website
-
http://www.biospace.com/
External link for BioSpace
- Industry
- Internet News
- Company size
- 11-50 employees
- Headquarters
- West Des Moines, Iowa
- Type
- Privately Held
- Founded
- 1985
- Specialties
- biotech jobs, pharma jobs, biotech news, pharma news, and life sciences news
Locations
-
Primary
3001 Westown Pkwy
#101
West Des Moines, Iowa 50266, US
Employees at BioSpace
-
Greg Slabodkin
-
Dr. D. Martin Alexander Gershon, MD, JD, MPH
AI & Digital Health Innovation Keynote•Linkedin “Top Voice” Venture Capital, Entrepreneurship, & Fundraising•Techstars Sr EIR•Goldman…
-
Angela Gabriel
Content Manager (Life Sciences Careers) at BioSpace
-
Lori Ellis (Katz)
Head of Insights
Updates
-
Artificial intelligence is making it faster to get drug candidates to the clinic, but to gain a competitive advantage, companies must have a strong foundation of data. https://hubs.li/Q02G2l850 #ai #artificialintelligence #drugpipeline #biospace
Opinion: To Realize AI’s Benefits, Don’t Lose Sight of Fundamentals | BioSpace
biospace.com
-
Investment in the development of new antimicrobials is falling rapidly, even as the global public health threat of antimicrobial resistance is growing increasingly severe worldwide. https://hubs.li/Q02G2m060 #pharma #antimicrobials #lifesciences #investment #biospace
Why Is Antimicrobial Resistance Not Getting Much Attention from Biopharma? | BioSpace
biospace.com
-
Preliminary data from a late-stage trial of Alnylam Pharmaceuticals's RNAi therapy for ATTR amyloidosis with cardiomyopathy appear strong, but details expected later this summer are critical. https://hubs.li/Q02G2kfQ0 #pharma #clinicaltrials #biospace
Alnylam Could Challenge Pfizer in ATTR-CM But Experts Want Full Data | BioSpace
biospace.com
-
After pulling its ALS drug Relyvrio from the market, Amylyx Pharmaceuticals has purchased Eiger BioPharmaceuticals’ GLP-1 avexitide, which has been studied for the treatment of hyperinsulinemic hypoglycemia. https://hubs.li/Q02G2jdc0 #pharma #GLP1 #biospace
Amylyx Pivots to GLP-1 Space, Acquires Phase III-Ready Asset from Eiger | BioSpace
biospace.com
-
The FDA has added atopic dermatitis to the label of Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)'s topical PDE4 inhibitor Zoryve for the treatment of patients six years of age and older. https://hubs.li/Q02G2g720 #pharma #regulation #biospace
FDA Approves Atopic Dermatitis Label Expansion for Arcutis’ Zoryve Cream | BioSpace
biospace.com
-
Eli Lilly and Company becomes the latest to make a major investment in immunology and inflammation, while antibody-drug conjugate biopharma Myricx Bio nets a large Series A round and new research highlights the potential and possible risks of GLP-1s. Tune in to the latest episode of The Weekly with Heather McKenzie, Greg Slabodkin and Tyler Patchen: https://hubs.li/Q02G1LgK0 #pharma #TheWeekly #biospace
Lilly’s I&I Play, ADC Investment and GLP-1 Momentum Persists | BioSpace
biospace.com
-
Biotech venture capital firm Flagship Pioneering is looking to fund companies focused on artificial intelligence, human health and sustainability, bringing the total raised since 2021 to $6.4 billion. https://hubs.li/Q02G0YRZ0 #finance #biospace
VC Firm Flagship Raises $3.6B to Create, Support 25 ‘Breakthrough’ Companies | BioSpace
-
The pharma giant announced Tuesday that Mikael Dolsten is leaving his role as chief science officer after more than 15 years. Pfizer is conducting an external search for a replacement, with Dolsten staying on to assist in the months-long process. https://hubs.li/Q02FRZVF0
Pfizer CSO Mikael Dolsten to Step Down After 15 Years Driving R&D | BioSpace
biospace.com
-
The Federal Trade Commission on Tuesday issued an interim report on the top pharmacy benefit managers, showing that they are generating massive profit at the expense of patients by inflating prescription drug costs. https://hubs.li/Q02FRXMG0 #pharma #finance #biospace
PBMs ‘Wield Enormous Power’ Over Patient Access to Affordable Drugs: FTC | BioSpace
biospace.com